FGP
MDGL icon

Freestone Grove Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Freestone Grove Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Buy
+1,552
New +$795K 0.01% 568

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Freestone Grove Partners's MDGL Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 1,552 shares worth $833K. The stake represents 0.01% of the portfolio and ranks #568 among its holdings.

413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Freestone Grove Partners held 1,552 shares of Madrigal Pharmaceuticals worth $833K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Freestone Grove Partners position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #568 holding.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.